PARP1 and cancer: While the effect was more pronounced in BRCA mutated cancers, the patients without BRCA mutations also showed a good response to niraparib and rucaparib, indicating that PARP inhibitors can be effective irrespective of the BRCA status (Mirza et al. 2016; Coleman et al. 2017; González-Martin et al. 2019).